about
Bleeding related to disturbed fibrinolysisNatural Products for AntithrombosisA novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.PAI-1 and t-PA/PAI-1 complex potential markers of fibrinolytic bleeding after cardiac surgery employing cardiopulmonary bypassFibrinolysis and the control of blood coagulation.Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungsPlasminogen Activator Inhibitor-1 Controls Vascular Integrity by Regulating VE-Cadherin TraffickingThe Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction.Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study.Semantic interrogation of a multi knowledge domain ontological model of tendinopathy identifies four strong candidate risk genes.Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysisEthanol and Cancer Induce Similar Changes on Protein Expression Pattern of Human Fibroblast Cell.Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause.Rare and unusual bleeding manifestations in congenital bleeding disorders: an annotated review.Genetic background of idiopathic pulmonary fibrosis.A diagnostic approach to mild bleeding disorders.Rapid generation of endogenously driven transcriptional reporters in cells through CRISPR/Cas9.Global assays of fibrinolysis.Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis.Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease.Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience.Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases.Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.Total hip arthroplasty and total knee arthroplasty in a patient with congenital deficiency of plasminogen activator inhibitor-1.7.5% NaCl Resuscitation Leads to Abnormal Clot Fibrinolysis after Severe Hemorrhagic Shock and its Correction with 7.5% NaCl Adenosine, Lidocaine, and Mg2.Influence of Plasminogen Activator Inhibitor -1 Gene Polymorphism on Renal Scarring After First Febrile Urinary Tract Infection in Infants.Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practiceRecurrent Arterial and Venous Thrombotic Events in a Patient with Psoriasis. Impact of PAI-1 Polymorphism: A Case Report
P2860
Q28070127-F1BD4484-9709-463B-A8B9-923192781EA6Q28084934-18A08527-CEAA-4D82-A9A7-325A5340F9B5Q34171094-6E8B846F-7FCA-48C0-8330-D62CD39FC741Q34461462-097B5384-24E3-44E0-8734-3706520777B7Q35039847-8BFE3EC6-7DD9-4BB2-87E7-DD1C098CE2EFQ35351530-25377840-4007-4E84-B747-36348FCE420DQ35880793-899F5C4D-22E1-4EDB-AF84-DAD052AEF136Q35931125-25E34ECE-1F01-4AE7-A0CD-3DC9D5F20E69Q36244144-549F19E1-EB07-4B6E-9E45-A2E2053CA39EQ36249248-BDF51BB6-881A-40ED-8993-300309D5D1C5Q36501203-141CB9AE-2A7F-46A7-82D8-311A74EF2BE9Q37119024-30D2608B-3070-4B4C-A2DC-8A8635B12F6DQ37409534-8E37B972-E880-4B36-9E38-DB26195E3168Q37592091-6DD85C83-B136-4145-823F-8AB0071FB451Q37620112-CFA08E39-28FC-4F8C-9F22-6901D270F145Q37923230-248A9F36-30B6-483C-B927-F4D780CBA46FQ38103596-7059DF3E-32FC-49A2-95BD-6DD788CDCD61Q38840603-820BD48E-F028-4F93-AF6D-C8DE4B06A862Q38881071-8EF80D9B-87AD-4D1E-8A43-3F842CA18D4DQ39301841-C5651C40-89A7-4498-B62F-E65EA3E58606Q39315148-48F914F4-0F2B-4F66-AF19-FD04D3DCB3C2Q39929468-D5A38EAC-C2F0-4F23-BC89-C103FE39E00DQ40287631-B8CA2080-C56C-4B88-A86A-9A05B3B19B50Q41877271-0B4EB13C-44A2-4803-9A53-556ADF52D7C5Q43613433-15962BAD-1782-42B0-AE85-80F82B3AF5E5Q45242524-4135A296-5D24-4B46-8241-E1119AC6A9CEQ45873187-BDAB106B-D3C8-474F-B4E6-6B3C56453112Q45884523-C1594BBE-D839-46C6-BB54-48669EAB8BE9Q55001681-23A544C5-BD3B-4093-97A3-E4C060DCAB55Q55317253-F1D83A94-29E8-4523-BBF7-96522F81294EQ57824750-61259C79-A501-41DD-9B37-8A2B6F2D2DB6Q58639427-9B4D6DFC-14ED-4F15-B586-40F22BA387C2
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Plasminogen activator inhibitor type 1 deficiency.
@en
Plasminogen activator inhibitor type 1 deficiency.
@nl
type
label
Plasminogen activator inhibitor type 1 deficiency.
@en
Plasminogen activator inhibitor type 1 deficiency.
@nl
prefLabel
Plasminogen activator inhibitor type 1 deficiency.
@en
Plasminogen activator inhibitor type 1 deficiency.
@nl
P1433
P1476
Plasminogen activator inhibitor type 1 deficiency.
@en
P2093
P304
P356
10.1111/J.1365-2516.2008.01834.X
P577
2008-11-01T00:00:00Z